














































































































Hyporesponsiveness	 to	 erythropoiesis-stimulating	 agents	 (ESA)	 and	 its	
association	 with	 adverse	 cardiovascular	 outcomes	 remains	 a	 considerable	









Hb	 between	 9	 to	 12	 g/dl.	 	 The	 primary	 study	 endpoint	was	 ESA	 requirement	
relative	 to	 Haemoglobin	 (Hb)	 level	 at	 the	 end	 of	 study	 period	 of	 6	 months.	
Secondary	 endpoints	 included	 safety	 analysis,	 Hb	 values,	 ESA	 dose	 and	





between	pentoxifylline	and	placebo	group	 (Mean	 (SD)	3.98	mcg/gm/dl	 (3.09)	
versus	4.91	mcg/gm/dl	(3.49)	respectively).	 	The	secondary	outcomes	did	not	
show	 any	 statistically	 significant	 change	 between	 pentoxifylline	 and	 placebo	



















































































































































































































































































































































































































































































































































































































































































































































































































































































degree	 of	 inflammation	 in	 CKD	 patients.	 Most	 of	 the	 guidelines	 recommend	












Unfortunately,	 about	 10-20%	 of	 haemodialysis	 patients	 show	 resistance	 or	








but	 still	 cost	 of	 care	 of	 such	 group	 of	 patient	 is	 high	 due	 to	 their	 frequent	
hospitalisations.	
	
Chronic	 inflammation	 is	 one	 of	 the	 major	 factors	 associated	 with	 ESA	
hyporesponsiveness	in	patients	with	CKD	and	end	stage	renal	disease	(ESRD)[53-
55].	 Higher	 ESA	 requirements	 are	 indicative	 of	 the	 risks	 associated	 with	 the	
potential	 cause	of	 ESA	 resistance	 such	 as	 high	 inflammation	 burden	 and	 non-
erythropoietic	effects	of	higher	ESA	dose.		
	
Several	 studies	 have	 also	 shown	 that	 there	 is	 a	 correlation	 between	 elevated	
levels	of	cytokines	such	as	TNF-α,	IFN-γ,	IL-1,	IL-6	and	erythropoietin	resistance	
in	haemodialysis	patients	[56-58].	Pro-inflammatory	cytokines	inhibit	erythroid	
progenitor	 cell	 proliferation	 and	 antagonise	 the	 anti-apoptotic	 action	 of	






6	 induction,	mediated	 through	BMP	signalling.	Raised	hepcidin	 concentrations	
	 32	
lead	 to	 functional	 iron	 deficiency	 as	 a	 consequence	 of	 down	 regulation	 of	
ferroportin	resulting	 in	 intracellular	accumulation	of	 iron	 in	macrophages	and	















vitamin	 C	 and	E	 in	 order	 to	 treat	 ESA	hyporesponsiveness	 but	 unfortunately,	
there	is	no	clear	evidence	to	support	any	of	these	interventions.	This	finding	has	







developing	 atherosclerosis	 and	 subsequently	 leading	 to	 plaque	 rupture	 and	
developing	 the	 dreaded	 complications	 such	 as	 acute	 coronary	 syndrome	 and	
stroke	[65,	66].	In	animal	studies,	leukocyte	recruitment	and	expression	of	pro-
inflammatory	 cytokines	 characterise	early	atherogenesis,	 and	 the	 inhibition	of	
inflammatory	mediators	mutes	 atheroma	 formation[67].	 Inflammation	 in	 CKD	































































































































































































































































































































• Navarro	 et	 al.	 treated	 7	 anaemic	 CKD	 patients	 not	 on	 dialysis	 with	
































































dialysis,	 severe	 hyper-parathyroidism,	 myelosuppressive	 medications,	 active	
infection	and	haematological	conditions	are	ruled	out.	Anaemia	of	CKD	is	treated	

















With	 this	 hypothesis,	 a	 single	 centre	 randomised	 placebo-controlled,	 double-
blinded	study	was	planned	to	assess	the	effect	of	Pentoxifylline	on	ESA	dose,	on	
surrogate	 markers	 of	 cardiovascular	 outcomes,	 safety	 and	 cytokine	 profile	 in	















































Prior	 to	 initiation	 of	 the	 study	 ethical	 approval	 was	 obtained	 from	 the	 East	
London	and	City	Research	Ethic	Committee	and	the	study	was	approved	by	the	







and	stored	for	 future	research	 in	PEAR	study	were	 later	analysed	for	cytokine	
profile	 included	 Transforming	 growth	 factor	 (TGF)	 gamma,	 Tumour	 necrosis	









enrolment.	 The	 eligibility	 criteria	 for	 patient	 enrolment	 in	 the	 study	 was	 as	
follows:	










• Receiving	 treatment	 with	 intravenous	 (I.V.)	 or	 sub-cutaneous	 (S.C.)	
erythropoietin	stimulating	agent	(ESA)	at	least	weekly	(i.e.	exclude	Mircera™	or	
other	 ESAs	 given	 fortnightly	 or	monthly)	 for	 a	minimum	 of	 8	weeks	 prior	 to	
administration	 of	 study	 agent,	 requiring	 doses	 to	 remedy	 ESA-resistance	
(requiring	greater	than	or	equal	to	6000	International	Units	(I.U)	equivalent	of	
ESA	 per	 week	 or	 if	 ESA	 resistance	 index	 is	 greater	 than	 or	 equal	 to	 6.5	 I.U	














• Clinically	 relevant	 abnormal	 history	 of	 physical	 and	mental	 health	 other	 than	
conditions	related	to	CKD	of	the	patient,	as	determined	by	medical	history	taking	
(as	judged	by	the	investigator).	
• Clinically	 relevant	 abnormal	 laboratory	 results,	 electrocardiogram	 (ECG),	 vital	






• Participation	 in	 an	 investigational	 drug	 trial	 in	 the	 3	 months	 prior	 to	
administration	of	the	initial	dose	of	study	drug.	







• Subjects	 with	 recent	 (3	 months)	 cerebral	 haemorrhage,	 extensive	 retinal	
haemorrhage,	acute	myocardial	infarction	and	severe	cardiac	arrhythmias.	
• Contraindications	 to	 magnetic	 resonance	 imaging	 (e.g.	 severe	 claustrophobia,	
	 50	
pacemaker,	defibrillators).	








Systematic	 non-compliance	 to	 medications	 was	 the	 primary	 criterion	 for	
premature	withdrawal	 from	the	study.	End-point	 tests	were	performed	(blood	
and	radiology)	if	the	patient	agreed	prior	to	formal	withdrawal	from	the	study.	








During	 the	study,	 the	patients	 continued	all	 their	 regular	 therapy.	 	 Initiating	a	




Concomitant	medications	were	 expected	 to	 include	 iron	 therapy	 on	 a	 regular	
basis	to	maintain	T	Sats	>25%	and/or	ferritin	>200	microgram	(µg)/L,	phosphate	
















1:1	 randomisation	 was	 stratified	 for	 diabetes	 status	 and	 ESA	 requirement.	
Patients	were	classified	into	four	groups	based	on	ESA	requirement	and	presence	
of	 diabetes.	 Patients	 were	 allocated	 into	 high	 ESA	 group	 if	 equivalent	 ESA	
requirement	was	>14,000	units	/	week.	Patients	were	allocated	to	study	drug	
according	 to	 recruitment	 sequence	 in	 each	 group.	 The	 drugs	 sequence	 had	
already	been	randomized	by	the	investigational	medicinal	product	IMP	supplier.	
















































of	 ESA	will	 be	 12000	 I.U./week	 (with	 standard	 deviation=500).	 If	 the	 placebo	














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.77	(2.37)	 5.03	(3.18)	 -0.25	 4.18	(2.30)	 3.83	(2.91)	 	0.34	 0.12	
Hb	
	
10.74	(.92)	 11.01	(1.30)	 -0.27	 11.34	(.89)	 11.14	(1.09)	 	0.19	 0.66	
ESA	 50.25	(23.94)	 52.95	(32.84)	 		-2.69	 44.29	(23.28)	 42.32	(28.59)	 1.96	 0.15	














































































































































































































































































































Outcome	 Placebo	(n=31)	 Pentoxifylline	(n=20)	 p	value	
	
SUV	max	 2.55	(0.65)	 2.68	(0.52)	 0.44	













































Outcome	 Placebo	(n	=	31)	 Pentoxifylline	(n=20)	 p	value	
SUV	Max	 2.53	(.47)	 2.61	(.53)	 0.64	
















































































































































	 Pentoxifylline	 Control	 P-value	
Number	 12	 17	 ns	
End	Diastolic	Volume	(mL)	 177	(83.03)	 150	(47.51)	 ns	
End	Systolic	Volume	(mL)	 78	(70.31)	 63	(28.93)	 ns	
Stroke	Volume	(mL)	 98	(33.69)	 87	(24.94)	 ns	
Ejection	Fraction	(%)	 59	(15.23)	 59	(9.09)	 ns	
Myocardial	Mass	(g)	 169	(77.74)	 133	(36.84)	 ns	

























































































29.17	(16.76)	 -4.36	 19.79	(14.11)	 24.58	(17.05)	 -4.78	 .40	
IL	6	 9.28	(13.56)		
	
15.57	(22.00)	 -6.32	 5.64	(7.47)	 11.06	(11.06)	 -5.42	 .32	
TGF	 4.82	(4.95)	
	
6.4	(5.2)	 -1.64	 6.59	(7.11)	 7.61	(6.77)	 -1.020	 .34	
IFN	
gamma	
































































































































































































































































































































































































































































































Fluid	overload	 29	 45	 <0.05	
Gastrointestinal	system	 9	 22	 0.05	
Access	related	-	non-infectious	 58	 63	 <0.05	
Access	-	infectious	 5	 11	 0.32	
Medication	change	 40	 65	 <0.05	







Genitourinary	system	 4	 8	 0.5	
Endocrinology	 10	 8	 0.16	
Skin	 4	 1	 0.07	
Deaths	 2	 0	 0.09	

















































































































































The	 results	 of	 our	 study	 are	 in	 contrast	 to	 another	 double-blind	 placebo	
controlled	 RCT	 published	 after	 the	 commencement	 of	 our	 study.	 In	 this	
multicentre	 trial,	53	patients	with	CKD	4	or	5D	with	ESA	hyporesponsiveness	





and	 control	 group	 (p=0.1).	 However,	 pentoxifylline	 significantly	 improved	 Hb	
































On	 the	other	hand,	 smaller	uncontrolled	 studies	discussed	 in	 the	 introduction	




This	 is	 in	 keeping	 with	 the	 hypothesis	 of	 inflammation-driven	 ESA	




pentoxifylline	 in	 ESA	 resistance.	 This	 could	 be	 attributed	 to	 comorbidities	
associated	 with	 advanced	 CKD	 patients	 on	 haemodialysis	 who	 subsequently	
suffer	from	ESA	resistance.	This	high-risk	cohort	of	patients	suffers	from	frequent	
spells	 of	 illnesses	 usually	 associated	with	 cardiovascular	 events	 and	 infective	
complications	which	could	mask	the	potential	beneficial	effect	of	Pentoxifylline	
resulting	 from	 its	 effect	 on	 pro-inflammatory	 cytokines	 demonstrated	 in	 our	
study.		Pentoxifylline	was	consistently	found	to	be	safe	in	haemodialysis	patients.		
	
Recently,	 the	 effect	 of	 pentoxifylline	 was	 studied	 in	 another	 inflammatory	
condition.	 A	 large	 multicentre,	 double	 blind	 study	 involving	 1103	 patients	
evaluated	 the	effect	of	pentoxifylline	on	acute	 alcoholic	hepatitis	 compared	 to	
prednisolone.	The	dose	of	Pentoxifylline	used	was	also	400	mg	OD.	This	study	did	
not	 show	 any	 beneficial	 effect	 of	 pentoxifylline	 compared	 to	 Prednisolone.	
Prednisolone	 was	 shown	 to	 improve	 short-term	 outcome	 in	 acute	 alcoholic	
hepatitis	[128].	
	
There	 is	 growing	 evidence	 that	 Diabetic	 nephropathy	 is	 an	 inflammatory	
condition.	Therefore,	newer	anti-inflammatory	agents	have	been	studied	to	halt	











given	 dose	 was	 tolerated	 well	 except	 for	 higher	 incidence	 of	 gastrointestinal	
symptoms	which	resolved	spontaneously	 in	 the	majority	of	patients.	 	Hence,	a	
higher	 dose	 of	 Pentoxifylline	 given	 for	 longer	 duration	 has	 shown	 significant	





improvement	 in	 ESA	 requirement	 despite	 some	 beneficial	 effects	 on	 overall	
cytokine	 exposure.	 The	 effect	 of	 Pentoxifylline	 was	 not	 translated	 into	 its	







conducted	 in	 a	 setting	 of	 a	 pragmatic,	 large	 cluster	 randomised	 trial.	 Higher	
dosing	of	pentoxifylline	could	be	considered	in	haemodialysis	patients	following	
an	appropriate	pilot	study.	Chronic	haemodialysis	setting	is	an	ideal	situation	for	
conducting	pragmatic	 clinical	 trials.	 	 	While	undergoing	haemodialysis,	patient	
encounters	are	regular	and	predictable.	A	significant	amount	of	clinical	data	 is	
already	collected	 for	routine	 clinical	 care.	National	 renal	registries	also	 collect	
various	aspects	of	this	dataset	in	the	majority	of	the	developed	world	[130].	
	
In	 conclusion,	 further	 studies	 are	 required	 with	 larger	 patient	 numbers	 to	
establish	 effect	 pentoxifylline	 for	 ESA	 hyporesponsiveness	 in	 haemodialysis	
	 107	
patients.	 Two-	 well	 designed	 RCTs	 have	 failed	 to	 recruit	 adequate	 numbers.	































al.	 demonstrated	 the	 effect	 of	 intensifying	 statin	 therapy	 on	 atherosclerotic	
plaque	 inflammation	 along	 the	 major	 blood	 vessels.	 83	 patients	 with	












due	 to	 the	 complex	 mechanism	 and	 a	 higher	 degree	 of	 inflammation	 in	
haemodialysis	patients.			
	
	Due	 to	 its	 anti-inflammatory	 action	 in	 dialysis	 patients,	 the	 effect	 of	
pentoxifylline	 on	 atherosclerotic	 plaque	 inflammation	was	 also	 studied.	 PEAR	
study	 was	 the	 first	 study	 to	 quantify	 atherosclerotic	 plaque	 inflammation	 in	
chronic	 haemodialysis	 patients.	 The	 analysis	 of	 baseline	 scans	 (before	








Pentoxifylline	 group	 failed	 to	 reach	 statistical	 significance	 compared	 to	 the	
placebo	group	after	six	months	of	treatment.	There	was	no	statistically	significant	
difference	 between	 the	 two	 groups	 for	 SUV	max	 as	well.	 In	 the	 Pentoxifylline	
group,	 there	was	 an	 improvement	 of	 TBR	 at	 the	 time	of	 follow	up	 scan	when	
compared	 with	 baseline	 scans.	 While	 in	 the	 placebo	 group,	 there	 was	
deterioration	 of	 TBR	 in	 follow	 up	 scans	 when	 compared	 to	 baseline	 scans.	
Therefore,	 even	 though	 statistically	 nonsignificant,	 the	 positive	 impact	 of	
Pentoxifylline	 demonstrated	 by	 PEAR	 study,	 in	 reducing	 or	 halting	














The	 cardiac	 MRI	 analysis	 was	 limited	 by	 a	 very	 small	 number	 of	 patients	










demonstrated	 that	 GFR	 was	 strongly	 correlated	 with	 arterial	 stiffness	 [136].	
Another	study	demonstrated	that	24	patients	on	chronic	haemodialysis	with	no	
history	 of	 coronary	 heart	 disease	 had	 significantly	 reduced	 aortic	 compliance	
similar	to	non-CKD	patients	with	advanced	coronary	artery	disease	[137].			
	











Blood	 pressure	 has	 been	 considered	 as	 a	 modifiable	 risk	 factor	 in	 the	
pathogenesis	of	arterial	stiffness,	but	its	role	in	ESRD	patients	remains	uncertain.	
A	study	of	150	patients	with	ESRD	demonstrated	that	pulse	wave	velocity	which	








































































































































































































































































In	 the	 current	 scenario,	 there	 is	 no	 proven	 specific	 intervention	 available	 to	
improve	 Cardiovascular	 outcomes	 in	 haemodialysis	 patients.	 The	 available	
evidence	 which	 is	 driven	 from	 small,	 short-term	 studies	 has	 not	 led	 to	 any	
significant	change	in	practice	in	the	CKD	population.	Therefore,	targeting	arterial	




Although	outcomes	are	statistically	 insignificant	yet	 the	data	 from	PEAR	study	





























































































































































































































































































































































































































































































































































15.1 Protocol: PEAR Study 
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TITLE OF THE PROTOCOL: 
 
A Single-Centre randomized placebo 
controlled, double blinded study of 
Pentoxifylline in End-Stage Renal Disease 
















Sponsor: Barts Health NHS Trust 
  
Representative of the Sponsor: 
 Sally Burtles 
 Director of Research Services and Business 
Development 
Joint  Research Management Office 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7260 
 Email: sponsorsrep@bartshealth.nhs.uk 
 
REC reference:   12/LO/1635 
 
EudraCT reference: 2011-006168-30 
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Chief Investigator Agreement Page 
 
 
The clinical study as detailed within this research protocol (Protocol PEAR_20March2013_v8-1), or 
any subsequent amendments, involves the use of an investigational medicinal product and will be 
conducted in accordance with the Research Governance Framework for Health & Social Care 
(2005), the World Medical Association Declaration of Helsinki (1996), Principles of ICH-GCP, and 
the current regulatory requirements, as detailed in the Medicines for Human Use (Clinical Trials) 





Chief Investigator Name: 




Chief Investigator Site: 




Signature and Date: 
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Statistician Agreement Page 
 
 
The clinical study as detailed within this research protocol (Protocol PEAR_20March2013_v8-1), or 
any subsequent amendments, involves the use of an investigational medicinal product and will be 
conducted in accordance with the Research Governance Framework for Health & Social Care 
(2005), the World Medical Association Declaration of Helsinki (1996), Principles of ICH-GCP, and 
the current regulatory requirements, as detailed in the Medicines for Human Use (Clinical Trials) 
















Signature and Date: 
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Investigator site: Barts Health NHS Trust 
Responsible investigator Prof Magdi Yaqoob 
Co-investigator(s) Dr S Fan,  
Dr F Pugliese,  
Dr C Davies,  
Dr S Petersen,  
Prof C Thiemermann 
 
Laboratory sites (describe for each assay) 
Assay Laboratory (name / adress) Contact person 
Chemistry Clinical Biochemistry 
Dr Sally Benton 
Consultant Clinical Scientist 
Barts Health NHS Trust 
 








• Lab Manager: Dr Steve Harwood  
• Department of Translational Medicine and Therapeutics, 
John Vane Building, 
William Harvey Research Institute, 
Charterhouse quare, London EC1  
 






Pharmacy Contact person 
Pharmacy Unit, 
Barts Health NHS Trust 









TITLE A Single-Centre randomized placebo controlled, double 
blinded study of Pentoxifylline in End-Stage Renal 
Disease Patients with Erythropoeitin resistance 
SHORT TITLE PEntoxifylline in Anaemia Resistant to erythropoietin 
(PEAR) 
Protocol Version 
Number and Date 
 
Protocol PEAR_29th Oct.2013_v 10-1 
Methodology 
 
A Single-Centre randomized placebo controlled, double 







Barts Health NHS Trust 
Rationale Unfortunately, a considerable proportion of ESRD patients 
exhibit a suboptimal haematologic response to ESA. In 
some patients, this has been attributed to elevated levels of 
inflammatory cytokines including TNF-a and IFN-g. 
Pentoxifylline specifically inhibits T-cell production of 
TNF-a and IFN-g and in a small uncontrolled study 





To study the effects Pentoxifylline in ESA resistant ESRD 
patients on haemodialysis  
 
Endpoints:  
The primary study end point is the ESA requirement 
relative to the Hb level. 
 
Secondary endpoints include: 
• Safety analysis  
• Hb values and ESA doses after 6 months of 
treatment. 
• Blood sampling will be performed at the start of 
each hemodialysis session every month.   
• Cardiovascular imaging will be performed at 
baseline and at 6 months. The effect IMP has on 
the following cardiovascular parameters will be 
examined: 
o mean target-to-background ratio across a 
substantial portion of artery (typically 
aorta, supraaortic vessels and femoral 
arteries) using 18-FDG-PET (time-of-
PEAR 
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flight). This will allow us to assess whether 
IMP has an anti-inflamatory effect on the 
blood vessels 
o vascular stiffness measures (e.g. aortic 
distensibility at three levels of aorta 
(mmHg-1), pulse wave velocity (m/s) and 
carotid distensibility (mmHg-1))using 
magnetic resonance (MR) imaging.  
o Measures of systolic and diastolic function, 
using cardiac MR (CMR) tagging 
techniques (strain (%) and strain-rate (s-1)) 
 
 







Main Inclusion Criteria 
 
Inclusion Criteria 
• Be able to read and understand the written consent 
form, complete study-related procedures, and 
communicate with the study staff; 
• Willing to comply with study restrictions; 
• Between 18 and 85 years of age (inclusive). 
• Diagnosis of clinically stable ESRD, as determined 
by the investigator; 
• Requiring regular dialysis therapy for at least 12 
weeks prior to first administration of study agent; 
 
• Receiving treatment with IV or SC erythropoietin 
receptor agonist at least weekly (ie exclude Micera 
or other ESAs given fortnightly or monthly) for a 
minimum of 8 weeks prior to administration of 
study agent, requiring doses to remedy EPO-
resistance (requiring greater than or equal to 
6000iu equivalent of EPO per week or if ESA 
resistance index is greater than or equal to 6.5iu 
/kg/wk/g Hb for equivalent EPO dose), with 
evidence of stable hemoglobin levels 
 
• Baseline hemoglobin values between 9.0 and 12.0 
g/dL before entering the study; 





We expect that the mean of the run-in and last 2 valid 
visits will be used for primary end-point analyses.  
 
Primary Endpoint Analysis: We shall be compare 
dEPO/kg requirement between the 2 groups using 
unpaired student t-test. 
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Glossary of Terms and Abbreviations 
 
° C Degree Celsius  
μg  Microgram  
AE Adverse Event  
ALT  Alanine aminotransferase  
AP Alkaline phosphatase  
AR Adverse Reaction 
AST  Aspartate aminotransferase  
BHT Barts Health Trust 
BUN Blood nitrogen urea 
CK Creatine kinase 
CKD Chronic Kidney Disease 
CMR Cardiac Magnetic Resonance Imaging 
CRF  Case Report Form  
(hs-)CRP (high sensitive) C- reactive protein 
CRF Clinical Research Form 
CSR  Clinical Study Report  
CV Cardiovascular 
DM Diabetes Mellitus 
DNA Deoxyribonucleic acid 
EC  European Community  
ECG  Electrocardiogram  
EMEA  European Medicines Agency  
EOT  End of Trial  
EPO Erythropoietin  
ESA Erythropoietin Stimulating Agents 
ESRD End Stage Renal Disease 
FBC Full blood count 
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
Glc glucose 
Hb Haemoglobin 
HD Haemodialysis (inclhaemodiafiltration or haemofiltration) 
hr(s) Hour(s) 
ICF Informed Consent Form  
ICH  International Conference on Harmonization  
IEC  Independent Ethics Committee  
IMP  Investigational Medicinal Product  
INF-g Interferon-g 
IP Investigational Product  
IRB  Institutional Review Board  
ITT Intention to Treat 
iu International units 
iv intravenous 
kg  Kilogram  
L Litres 
LFT Liver Function Tests 
MCH(C)  Mean Corpuscular Hemoglobin (Concentration)  
MCV  Mean Corpuscular Volume  
MedDRA Medical Dictionary for Regulatory Activities  
mg milligrams 
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MHRA Medicine Health Regulatory Authority 
mL Milliliter  
NA Not applicable  
NCS  Not clinically significant  
OTC  Over the counter (non-prescription medication)  
PET-CT Positron emission tomography – computed tomography 
PIS Patient Information Sheet 
PTH Parathyroid hormone 
RBC  
R&D 
Red Blood Cell  
Research and Development Department 
RLH Royal London Hospital 
SAE  Serious Adverse Event  
sc Subcutaneously 
SPC Summary of Product Characteristic 
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TNF-a Tumour Necrosis Factor-a 
TMF  Trial Master file  
Tsats Transferrin saturation 
U&E Urea & Electrolytes 
VS Vital signs  
WBC  White Blood Cell  
WHO  World Health Organization  
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1.1 Background  
Pentoxifylline (used for twenty years in the treatment of peripheral and cerebral vascular diseases),  
has potent haemorrheological and anti-inflammatory properties (secondary to inhibition of 
phosphodiesterases)  and (in 2  small, prospective, non-randomized phase 2a studies)improved 
haemoglobin levels in CKD patients with ESA-resistant anaemia.  
 
The use of ESA in resistant patients is very expensive: Twenty % of the patients on dialysis have 
ESA-resistance, which is a surrogate marker for excessive, all-cause and CV mortality. There are no 
specific therapeutic strategies available to these patients. Moreover, the health economic 
consideration for the treatment of ESA-resistant patients with ever increasing amounts of ESAis 
very significant. In BLT, the cost for ESA alone for 250 ESA-resistant patients amounts to £ 2.5 
Million per year which is the same cost as for the remaining 950 ESA-sensitive patients.  
 
If the proposed strategy is successful in ESA-resistant dialysis patients, then it may also be 
employed  in so-called ESA-sensitive’ patients in order to lower their ESA-requirements (and to 
make them ‘more sensitive’). 
 
1.2 Investigational Medicinal Product  
Pentoxifylline may also have other pleiotropic effects that may be due to direct action or mediated 
by enhanced tissue-protective effects of ESA that has been well documented. We are particularly 
interested in any possible synergistic actions of the direct anti-inflammatory action of pentoxifylline 
and ESA that may be beneficial to the vascular abnormalities that are found in ESRD patients.  
 
In fact, sudden cardiac and other cardiovascular events are the most common causes of death in 
ESRD patients. Surrogate markers of vascular abnormalities that have been found to correlate 
closely to morbidity and mortality include vascular calcification, pulse wave velocity and impaired 
vasodilation. 
 
We therefore wish to examine if Pentoxifylline is beneficial in ESRD patients with evidence of 
ESA-resistance. We wish to examine if the treatment improves ESA response and if we can detect 
any improvements in biochemical &radiological surrogate markers of vascular health. 
 
1.3 Preclinical Data  
SmPC for Pentoxifylline states, “Nothing of clinical relevance” for pre-clinical safety data. 
 
1.4 Clinical Data  
Pentoxifyllineis a licenced treatment for peripheral vascular disease because of its potent 
hemorrheological properties. It also has anti-inflammatory properties, mediated viainhibition of 
phosphodiesterase. 
 
Beneficial effects have been reported in idiopathic dilated cardiomyopathy, childhood type 1 
diabetes, and systemic vasculitis. Modest clinical effects have also been observed in rheumatoid 
arthritis. 
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Two small, prospective, non-randomised studies have demonstrated that: 
• Pentoxifyllinemay significantly improve haemoglobin levels in chronic kidney disease 
patients with ESA-resistant anaemia. Navarro et al treated 7 anaemic patients not on dialysis 
with oxpentifylline (oral 400 mg daily) for 6 months.  
• Haemoglobin levels significantly increased from 9.9 ± 0.5 to 10.6 ± 0.6 g/dL (p < 0.01). 
Similarly, Cooper et al used the same dose for 4 months in 16 EPO-resistant anaemic 
dialysis patients. Among the 12 patients who completed the study, mean haemoglobin 
concentration increased from 9.5 ± 0.9 to 11.7 ± 1.0 g/L (p = 0.0001). 
 
1.5 Rationale and Risks/Benefits  
The following are side-effects listed in the SmPC for Pentoxifylline: 
These adverse reactions have been reported in clinical trials or post-marketing. Frequencies are 
unknown.  
System Organ Class Adverse Reaction 
Investigations  Transaminases increased  
Cardiac disorders  Arrhythmia, Tachycardia, Angina Pectoris  
Blood and lymphatic system disorders  Thrombocytopenia  
Nervous system disorders  Dizziness, headache, meningitis aseptic*  
Gastrointestinal disorders  Gastrointestinal disorder, Epigastric discomfort, 
Abdominal distension, Nausea, Vomiting, 
Diarrhoea  
Skin and subcutaneous tissue disorders  Pruritus, Erythema, Urticaria, Hot flush  
Vascular disorders  Haemorrhage**, Hypotension  
Immune system disorders  Anaphylactic reactions, Anaphylactoid reaction, 
Angioedema  
Hepatobiliary disorders  Cholestasis  
Psychiatric disorders  Agitation, Sleep disorder  
Respiratory disorders  Bronchospasm  
Description of selected adverse reactions 
* Reports of aseptic meningitis were predominantly in patients with underlying connective tissue 
disorders  
** A few very rare events of bleeding (e.g. skin, mucosa) have been reported in patients treated 
with Trental with and without anticoagulants or platelet aggregation inhibitors. The serious cases 
are predominantly concentrated in the gastrointestinal, genitourinary, multiple site and surgical 
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wound areas and are associated with bleeding risk factors. A causal relationship between Trental 
therapy and bleeding has not been established. Thrombocytopenia has occurred in isolated cases. 
PEAR 
Protocol: PEAR_14Oct2015_v11-1  Page 15 of 41 
 
2 Trial Objectives and Design 
2.1 Trial Objectives  
To study the effects Pentoxifylline in ESA resistant ESRD patients on haemodialysis 
 
Endpoints:  
Primary study endpointis the ESA requirement relative to the Hb level. 
 
Secondary endpoints include: 
• Safety analysis  
• Hb values and ESA doses after 6 months of treatment. 
• Cardiovascular imaging will be performed at baseline and at 6 months. The effect IMP has 
on the following cardiovascular parameters will be examined: 
o mean target-to-background ratio across a substantial portion of artery (typically 
aorta, supraaortic vessels and femoral arteries) using 18-FDG-PET (time-of-flight). 
This will allow us to assess whether IMP has an anti-inflamatory effect on the blood 
vessels 
o vascular stiffness measures (e.g. aortic distensibility at three levels of aorta (mmHg-
1), pulse wave velocity (m/s) and carotid distensibility (mmHg-1))using magnetic 
resonance (MR) imagin 
o Measures of systolic and diastolic function, using cardiac MR (CMR) tagging 
techniques (strain (%) and strain-rate (s-1)) 
 
 
2.2 Trial Design  
Study Design: This is a single-centre, randomised double blinded placebo controlled trial of100 
patients with ESRD on dialysis. Patients will receive either Pentoxifylline 400mg once a day or 
placebo for 6 months with a further 2 month follow-up after therapy is stopped. Randomisation will 
be stratified for diabetes mellitus status and ESA requirement (adjusted for Hb). 
 
Run-in Period: All subjects will undergo a run-in period of 2 weeks so that baseline haemoglobin 
levels can be measured once every week (+/- 3 days) so that we will have 3 values prior to starting 
IMP or placebo. 
 
Drugs and Dosages: Study drug will be given orally and at a dose of 400mg once a day. This dose 
was previously shown to be well-tolerated in ESRD patients and could suppress ex-vivo T-cell 
generation of TNF-a and IFN-g. 
 
The dose of ESA for each patient will remain unchanged unless consecutive Hb values are <10.0 or 
>12g/dl (or for clinical indications). This reflects the Local Barts Health NHS Trust Renal Protocol 
for managing Hb / ESA dose. Intravenous iron supplementation will be given in accordance with 
the Local Barts Health NHS Trust Renal  protocol. These protocols are listed in section 5.  
 
































2 week Run-In Period 
6 month Treatment Period 






Randomisation Arm A 
Arm B 
2 week Run-In Period 
6 month Treatment Period 
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3 Subject Selection 
3.1 Number of Subjects and Subject Selection  
We shall aim to recruit and treat a maximum of 100 patients (in each group) with end-stage renal 
disease established on dialysis. Although the power calculation below suggests we only require 30 
patients (in each group) to reach the end of the 6 month treatment to achieve the statistical power 
detailed below, there is a very high drop out rate because of death and transplantation. We therefore 
do not expect to recruit more than 100 patients/group and it is possible that 30/group patients will 
be sufficient if drop-out rates are lower than expected. 
 
Patients with ESA resistance defined as receiving treatment with IV or SC erythropoietin receptor 
agonist at least weekly (ie exclude Micera or other ESAs given fortnightly or monthly)for a 
minimum of 8 weeks prior to enrolment, requiring greater or equal to 6000 IU equivalent of EPO 
per week to achieve stable hemoglobin levels 
 
 
All subjects will be screened for eligibility within 28 days before enrollment, based upon data 
obtained from the most recent clinical visit(s). The population will consist of patients of either 
gender, aged 18-85 years (inclusive). 
 
3.1.1 Power calculation 
From internal audit data on ESA usage, we assume the average dose of ESA will be 12000iu/week 
(with SD=500) 
If the placebo group have Hb=10g/dl, the ESA/Hb ratio = 1200 
 
The study by Cooper et al showed that 4 months treatment increased Hb levels by 25%. 
We wish to power this study to demonstrate that IMP will increase ESA response by 5% 
 
If we assumed the SD for ESA/Hb = 100, this will mean that for an alpha level of 5% (95%CI) and 
a beta level of 5% (statistical power of 95%) we shall need 30 patients in each group. We assume 
that there will be a 50% drop out (transplantation and patient withdrawal) so we plan to recruit no 
more than 100 patients/group 
 
3.2 Inclusion Criteria  
Eligibility for study participation will be based upon data obtained from the most recent clinical 
visit(s). In addition, recent medical history will be obtained prior to enrolment. To be eligible for 
study participation, subjects must meet all of the following criteria: 
 
• Be able to read and understand the written consent form (with the help of a translator if 
necessary), complete study-related procedures, and communicate with the study staff; 
• Willing to comply with study restrictions; 
• Between 18 and 85 years of age (inclusive). 
• Diagnosis of clinically stable ESRD, as determined by the investigator; 
• Requiring regular dialysis therapy for at least 12 weeks prior to first administration of study 
agent; 
• Last hemoglobin value at time of consent between 9.0 and 12.0 g/dL before entering the 
study; 
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• Receiving treatment with IV or SC erythropoietin receptor agonist at least weekly (ie 
exclude Micera or other ESAs given fortnightly or monthly) for a minimum of 8 weeks prior 
to administration of study agent, requiring doses to remedy EPO-resistance (requiring 
greater than or equal to 6000iu equivalent of EPO per week or if ESA resistance index is 
greater than or equal to 6.5iu /kg/wk/g Hb for equivalent EPO dose), with evidence of stable 
hemoglobin levels 
 
• Serum folate and vitamin B12 levels are normal and T-sats>25% and / or ferritin > 200 
mcg/l  (last result prior to consent). 
 
 
3.3 Exclusion Criteria  
Eligibility for study participation will be based upon data obtained from the most recent clinical 
visit(s). In addition, recent medical history will be obtained prior to enrollment. If a subject displays 
any of the following criteria, he or she may not be enrolled in the study: 
 
• Clinically relevant abnormal history of physical and mental health other than conditions 
related to chronic kidney disease of patient, as determined by medical history taking (as 
judged by the investigator); 
• Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings other 
than conditions related to chronic kidney disease of patient (as judged by the investigator); 
• Subject has uncontrolled hypertension (in the opinion of the clinician); 
• Subject is unable to refrain from the use of disallowed concomitant medication from one 
week prior to the first study drug administration until follow-up assessments (see section 
3.3); 
• Participation in an investigational drug trial in the 3 months prior to administration of the 
initial dose of study drug  
• Subject has undergone major surgery within 3 months prior to screening; 
• Any other condition that in the opinion of the investigator would complicate or compromise 
the study (e.g. known haemoglobinopathy), or the well being of the subject. 
• Females of child-bearing potential who are not willing to use contraception for the duration 
of the study. 
• Females who are breast feeding. 
• Subject is known hypersensitivity to the active constituent, pentoxifylline other methyl 
xanthines or any of the excipients.  
• Subjects with recent cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial 
infarction and severe cardiac arrhythmias 
• Contraindications to magnetic resonance imaging (e.g. severe claustrophobia, pacemaker, 
defibrillators, etc.) 
• Subjects who are on (or are due to start) immunosuppressive and anti-inflammatory drugs 
except Asprin at a dose of ≤ 300mg/d. 
 
3.4 Criteria for Premature Withdrawal  
Systematic noncompliance may culminate in a patient’s withdrawal from the study.  
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We would perform the end-point tests (blood and radiology) if the patient agrees prior to formal 
withdrawal from the study. 
 
The 1 month safety follow-up period (including blood tests) will also be performed if the patient 
agrees. 
 
4 Investigational Medicinal Products (IMPs) 
IMP: Overencapsulated Pentoxifylline,  
Placebo: matching overencapsulated cellulose 
 
4.1 Formulation of IMP 
Capsules 
 
4.2 IMP Supply  
IMP and placebo are manufactured and supplied by Mawdsleys.  
 
 
4.3 Prescription of IMP  
A specifically designed Clinical trial prescription will be used for this study.  
4.4 Preparation and Administration of IMP  
The IMP will be given orally at a dose of Pentoxifyline 400mg once a day. 
 
4.5 Packaging and Labelling of IMPs  
A specifically designed Clinical trial label will be used for this study  
4.6 Accountability/Receipt /Storage and Handling of IMP  
The supply of IMP and Placebo will be shipped to Pharmacy at BHT. 
Pharmacy will store and dispense study drugs for patients. 
Drugs will be collected by Research Nurse or delegated investigator and handed to patients in 
study. 
Drug accountability: All treatments for the study will be stored in the Department of Pharmacy of 
BHT until dispensing when it is required.  
 
 
4.7 Dispensing of IMP  
Pharmacy at BHT will dispense IMP 
 
4.8 Prior and Concomitant Therapies  
During the study the patients will continue all their regular therapy. Initiating a drug with known 
anti-inflammatory properties will be avoided. If this has to be done because of the clinical condition 
of the patient, study drug administration will be discontinued, and replacement of the patient may 
be considered. Concomitant medications that are to be expected includeing iron therapy on a regular 
basis to maintain Tsats>25% and/or ferritin >200, phosphate binders, statins, medication to treat 
hyperparathyroidism, antihypertensive agents and other drugs to treat known complications of renal 
failure. 
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In general, concomitant medication resulting in non-eligibility includes all medication that in the 




4.9 Return/Recall or Destruction of IMP   
Unused drugs will be collected from patients. Accountability by pill counting will be performed  by 
the reseach team and drugs then returned to pharmacy for destruction. 
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5 Study Procedures 
5.1 Informed Consent Procedures 
Patient information sheet and consent form are separate to this protocol. 
 
A member of the clinical team looking after the patient will approach the potential subject. This will 
usually be done whilst they are undergoing their regular dialysis or waiting for their dialysis. 
Patients attend x3/wk for their dialysis, so we would expect them to consider the proposal and if 
they agree to sign the informed consent (this may be performed either by the clinical team member 
or a member of the research team). Consent will be countersigned by PI or Local Collaborator 
delegated by the PI on the delegation log prior to any treatment being given. And that any Nurse 
undertaking this role will be trained to do so and evidence of this will be in the TMF 
 
Patients attend hemodialysis x3/week indefinitely so it is possible for patients to take days or even 
weeks to decide. 
 
Use of independent  translators will be permitted. 
 
Patients generally attend hemodialysis x3/week until they die, get transplanted or move away (but 
the last of these is relatively rare). We therefore believe there is opportunity and it will be easy for 
the research team to feedback information to patients. 
 
5.1 Screening Procedures  
A member of the clinical  care team will use the electronic Renal Database to identify potential 
subjects. 
 
The screening/identification will be performed by a member of staff who has clinical 
responsibilities for renal patients, particularly hemodialysis patients 
 
5.2 Randomisation Procedures (if applicable)  
Allocation ratio and any stratification factors (with levels): 1:1 randomisation stratified for 
Diabetes status and and ESA requirement (adjusted for Hb). 
 
Generation of randomisation codes (manual or automated process): Patients will be allocated 
to study drug according to recruitment sequence. The drugs sequence will be been randomized by 
the IMP supplier. Method of randomisation by IMP supplier will be described in a separate  
randomisation procedure document. 
 
Individual responsible for randomisation and documentation: Study CI or delegated research 
person will record the recruitment number during the consent procedure. 
 
Access to code break in an emergency: Code Break envelopes will be kept in  a locked  Office , 
that can be accessed after contacting nominated Research Persons. 
 
5.3 Schedule of Treatment for each visit  
IMP: Oral Pentoxiphylline 400mg once a day  
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Placebo: Equivalent capsule once a day 
 
5.4    Schedule of Assessment  
Subjects will attend their Dialysis Unit (run by BHT )for their standard hemodialysis on Day 1 
(visit 1).Subjects will be entered in a run-in period for 2 weeks where biochemistry and 
haematology will be measure weekly (+/-3 days) to establish baseline. All blood tests will be taken 
prior to a dialysis session and preferably after an inter-dialytic gap of 48hrs. If the ESA dose 
changes in the run-in period, the patients will be withdrawn.  
 
Patients will be randomized if the subject meets the inclusion criteria: Subjects will return to the 
dialysis unit,according to their normal dialysis schedule.During weeks 3-29,subjects will be treated 
with either IMP or placebo. These will be provided to the patients during the monthly visits. 
Subjects will be asked to return unused medication for compliance check. 
 
Haematology and Chemistry will be checked every month (+/- 7 days) – see schedule of blood tests. 
All blood tests will be taken prior to a dialysis session and preferably after an inter-dialytic gap of 
48hrs. These tests will include: Hb, Hct, CRP. These monthly blood tests will be taken as part of the 
patients’ standard care and performed in the same local lab as the “additional” “Run-in” (weekly) or 
“Off-Treatment” (fortnightly) blood tests (that are restricted to Hb, Hct and CRP). 
 
After week 29, treatment (IMP or placebo) will be stopped. Subjects will be asked to return any 
remaining unused medication. Haematology and Chemistry will be checked every fortnight (+/- 3 
days) – see schedule of blood tests. All blood tests will be taken prior to a dialysis session and 




The investigator or study physician will thoroughly explain the nature and purpose of the study to 
each subject, as well as the associated procedures and any expected effects and adverse reactions 
before any study-specific screening procedures are conducted. The subject will be provided with a 
Subject Information Sheet and given sufficient time and opportunity to inquire about the details of 
the study and to decide whether to participate. If he or she wishes to participate in the study, the 
subject will be asked to sign and date an Informed Consent Form (ICF). Study eligibility will be 
based on investigation of the subject status, after inspection of the following parameters: 
 
§ Check of inclusion and exclusion criteria (as described in this protocol); 
§ Demographics, including gender, race; 
§ Complete medical history from 30 days before screening; 
§ Hematology, coagulation, clinical chemistry of most recent clinical visit will be recorded; 
§ Plasma CRP level. 
§ ESA dose 
 
Selected subjects who proved to be eligible candidates after investigation of subject status will be 
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including end of study 
visit) 
-2 -1 1 - 26 26-30 
24hr Urine collection  x  x 
Hematology, Clinical 
Chemistry 1 
X X  X 
Blood to be taken for storage 
if separate consent obtained 
X X X X 
Drug Administration    X  
Vital signs 2 X X X X 
Adverse Events 3   ß--------------------------------------à 
Concomitant medication 3   ß--------------------------------------à 
1Hematology and clinical chemistry assessments before dialysis. 
2Including pulse rate and supine BP pre-dialysis. 
3Adverse events and concomitant medication (including the dose of ESA) will be collected from signing the ICF at 
screening until last visit. 
 
Consent will be obtained prior to the start of Visit 1 dialysis. 
 
 
Visit 1 (week -2) 
• Arrival at Barts Health Trust (time of day dependent on hemodialysis scheme) 
• Vital signs 
• Signs and symptoms recording (pre-dialysis, pre-study medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs. 
• Hematology, clinical chemistry and hs-CRP; 
• Haemodialysis; 
 
Visit 2 (on week -1) 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Vital signs; 
• Signs and symptoms recording (pre-dialysis, pre-study medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs.  
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA; 
• Haemodialysis; 
• Give bottle for patient to collect 24hr urine output (to be collected at next dialysis) 
 
RANDOMISATION will be performed prior to visit 3 
 
Visits 3-8; monthly i.e. weeks 1-26 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Vital signs; 
• Signs and symptoms recording (pre-dialysis, medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs. 
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA(monthly) 
• Haemodialysis; 
• Collect unused medication and give IMP/placebo for another month. 
• Additional visits may be made by the investigators particularly during the first month to ensure 
patient compliance and to record any AR. These visits will be recorded in the CRF by the most 
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recent visit number followed by a letter suffix (e.g. visit 3-A or 3-B). 
 
Visit 9 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Vital signs;12-lead ECG (pre-dialysis); 
• Signs and symptoms recording (pre-dialysis, medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs.  
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA(monthly) 
• Hemodialysis; 
• Give bottle for patient to collect 24hr urine output (to be collected at next dialysis) 
 
 
Visit 10 - 11; fortnightly i.e. weeks 28 - 30 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Adverse Event recording including any medication changes; 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs.  




Protocol for Intravenous Iron Dosing (Venofer, iv) – Local Protocol 
 
Ferritin Dose of iv Fe Frequency 
<100 100mg Twice a week 
100-200 100mg Once a week 
200-500 100mg Once every 2 weeks 
>500  nil 
 
 
Protocol for ESA Dosing (Local Protocol): 
Target Hb range will be 10 -12g/dl. ESA dose will be increased or decreased by 25-50% depending 
on Hb (2 consecutive readings) 
Hb (g/dl) Dose change of ESA 
>15 Stop ESA and venesect 1 unit blood or discard 1 HD circuit aft HD 
14-15 Nil – ESA stopped 
13-14 Cut 50% 
12-13 Cut 25% 
9 – 10 Increase 25% 
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5.5 Follow up Procedures  
Haematology and Chemistry will be checked every fortnight (+/- 3 days) – see 
schedule of blood tests. All blood tests will be taken prior to a dialysis session and 
preferably after an inter-dialytic gap of 48hrs. This “Off-Treatment Follow-up Period” 
will last for 1 month. 
5.6 Laboratory Assessments  
“Standard Lab” Tests for the study will be: Hb, Hct and CRP. 
Cytokine profiles and DNA telomere lengths will also be measured. 
However, we note that the standard care of HD patients at Barts Health Trust undergo 
regular monthly blood tests that include these and more extensive “LFT” and “Bone 
Profiles”. These results will be available to the researchers. 
 






Clinical biochemistry 1x serum 7 12 84 
Blood to be taken if 
separate consent given 
permitting storage of 
blood 
 
1xserum 7 12 84 
1x EDTA 3.5 12 42 










5.7 Radiology Assessments  
Cardiovascular imaging will be performed at baseline and at 6 months. The effect 
IMP has on the following cardiovascular parameters will be examined: 
• mean target-to-background ratio across a substantial portion of artery 
(typically aorta, supraaortic vessels and femoral arteries) using 18-FDG-PET 
(time-of-flight). This will allow us to assess whether IMP has an anti-
inflamatory effect on the blood vessels 
• vascular stiffness measures (e.g. aortic distensibility at three levels of aorta 
(mmHg-1), pulse wave velocity (m/s) and carotid distensibility (mmHg-
1))using magnetic resonance (MR) imaging. 
For further details, refer to Appendix 1 and 2 
 
5.8 End of Study Definition  
This will be considered to be after the last visit of the last participant and 6 months 
after analysis of end-point evaluations. 
 
5.9 Procedures for unblinding (if applicable)  
Emergency Unblinding Procedures including Out of Hours: 
• Uncoding envelopes will be kept in the Renal Office (locked). Permission 
to access will be given by: Prof M Yaqoob or Dr S Fan or Research Clinic 
Fellow (to be appointed). Contact details will  be with switchboard at Barts 
Health NHS Trust.  
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• After a patient is unblinded, the patient will be given an option to undergo 
the end-point tests and the 1 month “off drug” follow up. 
 
Unblinding should only occur in the case of a medical emergency. 
 
5.10 Subject Withdrawal  
Subjects can leave the study at any time for any reason if they wish to do so without 
any consequences. The responsible investigator can also withdraw a subject if 
continuing participation is in his opinion deleterious for the subject’s well being. 
Subjects can also be withdrawn in case of protocol violations and non-compliance (as 
deemed significant by the investigators).  
 
5.11 Data Collection and Follow up for Withdrawn Subjects  
In case of withdrawal because of severe or serious adverse event haematological, 
blood chemistry and urine laboratory tests or other special examinations may be 
performed. 
 
Dropouts will not be re-included in the study. Their inclusion and treatment numbers 
must not be re-used. Dropouts due to withdrawal of informed consent or non-study 
drug related events might be replaced in order to obtain a sufficient number of 
subjects completing the study. The possible need for replacement of dropouts will be 
discussed by the primary investigator and responsible medical officer of the Sponsor.  
 
When a subject withdraws from the study, the subjects will be asked if they are 
willing to continue in the 1 month “non-treatment” study period. When a subject 
withdraws, the second radiological assessment may be conducted with patient 
consent. However, the patients are made aware in the PIS that audits of patients’ 
blood results are continuously performed as part of standard  NHS care within the 
Renal Unit at Barts Health Trust  and this will continue. 
 
 
All adverse events and concomitant medication will be entered in the CRF. 
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6 Laboratories (if applicable)  
6.1 Local Laboratories  
Laboratory for the Biochemistry and Haematology tests will be the Pathology 




6.2 Sample Collection/Labelling/Logging  
The laboratory will be blinded to the study drug allocation. Patient samples will not 
be anonymised or coded. The results of study biochemistry and haematology tests will 
be available to clinicians looking after the patients for clinical governance reasons. 
 
Blood (if separate consent if given) will be stored at -70C (with a target of 60mins 
between phlebotomy and storing at -70C). 
Standard biochemical and haematological samples will be kept at room temp and 
delivered through the hospital portering system. 
 
All blood tests will be taken prior to a dialysis session and preferably after an inter-
dialytic gap of 48hrs.  
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7 Pharmacovigilance  
7.1    General Definitions 
7.1.1 Adverse Event (AE)/ Adverse Reaction (AR) / 
Serious Adverse Event (SAE) or Serious 
Adverse Reaction (SAR) 
Adverse events are defined as any undesirable experience occurring to a subject 
during a clinical trial, whether or not considered related to the investigational drug. 
All adverse events reported spontaneously by the subject or observed by the investiga-
tor or his staff will be recorded on the adverse event data collection form. The 
intensity of these adverse events will thereby be graded by the investigator on a three-
point scale as defined below: 
 
Mild discomfort noticed but no disruption of normal daily activity 
Moderate discomfort sufficient to reduce or affect normal daily activity 
Severe inability to work or perform daily activity 
 
The chronicity of the event will be classified by the investigator on a three-item scale 
as defined below: 
 
Single occasion single event with limited duration 
Intermittent several episodes of an event, each of limited duration 
Persistent event which remained indefinitely 
 
For each adverse event the relationship to drug (definite, probable, possible, 
unknown, definitely not) as judged by the investigator as well as eventual actions 
taken will be recorded. The occurrence of an adverse experience that is fatal, life-
threatening, disabling or requires or prolongs in-patient hospitalisation or causes 
congenital anomaly will be described according to guidelines as "serious" adverse. 
Important medical events that may not be immediately life threatening or result in 
death or hospitalisation may be considered a serious adverse event when, based on 
appropriate medical judgement, they may jeopardise the patient or may require 




7.2 Notification and reporting Adverse Events or Reactions 
If the AE is not defined as SERIOUS, the AE is recorded in the study file and the 
participant is followed up by the research team. The AE is documented in the 
participants’ medical notes and the CRF. 
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7.3.1  Serious Adverse Event (SAEs)  
All SAEs will be recorded in the subjects’ medical  notes, the CRF, the sponsor SAE 
form and reported to the Joint Research Management  Office (JRMO) within 24 hours of 
the CI or PI or co-investigators becoming aware of the event.  Nominated co-
investigators will be authorised to sign the SAE forms in the absence of the CI at the 
co-ordinating site or the PI at the participating sites.  
 
The following SAEs do not have to be reported but will be captured by the 
investigators: 
• Any routine surgery/procedure that is related to dialysis access (Peritoneal 
dialysis and haemodialyis, e.g. for malpositioned, non-functioning PD 
catheters or for creation of AV-graft fistulae). 
• Any surgery/procedure that had been planned prior to trial enrollment. 
• Any admissions for renal transplantations 
• Any admission that are known to be related to HD such as infections, 
inadequate dialysis, problems with access, hypotension, fluid overload. 
• Any admission for related to missed dialysis sessions. 
 
 
7.3.2 Suspected Unexpected Serious Adverse 
Reactions (SUSARs)  
Will be reported to the JRMO/ main REC within 48 hours of the CI or co-investigator 
becoming aware of the event. SUSARs should be reported to the sponsor (JRO 
Office) within 24 hours as the sponsor has a legal obligation to report this to the 
MHRA within 7 days (for fatal or life-threatening SUSARs) or 15 days for all other 
SUSARs. The CI will need to complete the SUSAR  form in conjunction with the 
sponsor SAE form to be sent to the MHRA by the sponsor.  
 
The original and any subsequent follow up of Serious Adverse Event Forms and 
SUSUAR forms (where applicable), together with the sending  confirmation sheet 
must be kept with the TMF at the study site. 
 
7.4 Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the 
clinical trial subjects from any immediate hazard to their health and safety, in 
accordance with Regulation 30. The measures should be taken immediately. In this 
instance, the approval of the Licensing Authority Approval prior to implementing 
these safety measures is not required. However, it is the responsibility of the CI to 
inform the sponsor, Main Research Ethics Committee (via telephone) and the MHRA 
(via telephone for discussion with the medical assessor at the clinical trials unit) of 
this event immediately.  
 
The CI has an obligation to inform both the Sponsor,MHRA and Main Ethics 
Committee in writing within 3 days, in the form of a substantial amendment. The 
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7.5 Annual Safety Reporting  
The Development Safety Update  Reports (DSUR) will be sent by the CI to the 
sponsor, the MREC and MHRA (the date of the anniversary is the date on the “notice 
of acceptance letter” from the MHRA) using the Sponsors DSUR template form. The 
CI will carry out a risk benefit analysis of the IMPs encompassing all events having 
arisen on the trial.  
 
The CI will send the Annual Progress Report to the main REC using the NRES 
template (the anniversary date is the date on the MREC “favourable opinion” letter 
from the MREC) and to the sponsor. 
 
Procedures for reporting blinded SUSARs 
Treatment code for the patient is broken in the reporting of a SUSAR. However, the 
blind should be maintained, where possible and appropriate, for staff that are involved 
in data analysis and interpretation.  
 
It is recommended that in the case of a blinded study, the case is assessed for 
seriousness, expectedness and causal relationship as if it was the tested IMP that 
caused the reaction. If the case appears to be a SUSAR then it should be unblinded . 
 
If the administered product is the tested IMP, the case would be reported as a SUSAR 
to the MHRA/ appropriate Main Research Ethics Committee. 
 
If the administered product is a comparator with a marketing authorisation, the 
adverse reaction should be reassessed for expectedness according to the study 
protocol. If the adverse reaction is unexpected then the SUSAR should be reported; 
otherwise it is an expected serious adverse reaction which still requires reporting to 
the sponsor within 24 hours. 
 
7.6 Overview of the Safety Reporting 
Process/Pharmacoviligance responsibilities 
The CI has the overall pharmacovigilance oversight responsibility. The CI has a duty 
to ensure that pharmacovigilance monitoring and reporting is conducted in accordance 




If a patient becomes pregnant whilst involved  in this  CTIMP, it is not considered to 
be an SAE or an AE. However, it is an event that requires monitoring and follow up. 
If a patient, or his partner, becomes pregnant whilst enrolled in a CTIMP in which the 
foetus has been exposed to an investigational medicinal product, immediate reporting 
to the sponsor is required (within one working day of the PI/CI becoming aware of the 
event) using a JRMO pregnancy template form. The CI/PI has the responsibility to 
ensure that the pregnancy form is completed and sent to the sponsor within the agreed 
timelines. Please state whether the patient can continue on the study or whether the 
patient has to be prematurely withdrawn from the study here. 
 
The PI/CI also must follow up the pregnancy until delivery as well as monitoring the 
development of the newborn for the appropriate time (1 month) after birth. Any 
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events that occur during this time that could be considered to be a SAE must be 
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8 Statistical Considerations 
Missing and spurious data 
Data will undergo review to identify missing and spurious data. The data review will 
be an integral part of the report and includes the decisions on and documentation of 
such data. 
Only subjects with a baseline sample and at least one sample obtained during the 
treatment phase will be included in the analysis. Subjects who have discontinued at 
any time will undergo safety evaluations; reasons for discontinuation will be 
evaluated. Statistical plan and methods to be employed 
The statistics of this study entails a “per protocol” analysis and an Intention to Treat 
analysis where the last follow-up data point is carried over. 
 
Selection of subjects to be included in the analysis 
For intention to treat analysis, all data that meaningfully contribute to the objectives 




8.1 Primary Endpoint Efficacy Analysis  
We shall be compare dEPO/kg requirement between the 2 groups using unpaired 
student t-test. We expect that to compare the means of the run-in and last 2 visits of 
each patient will be used for primary end-point analyses (ITT), and the last 2 visits of 
each patient when taking IMP or placebo (Per Protocol). 
 
 
8.2 Sample Size  
From internal audit data on ESA usage, we assume the average dose of ESA will be 
12000iu/week (with SD=500) 
If the placebo group have Hb=10g/dl, the ESA/Hb ratio = 1200 
 
The study by Cooper et al showed that 4 months treatment increased Hb levels by 
25%. 
We wish to power this study to demonstrate that IMP will increase ESA response by 
5% 
 
If we assumed the SD for ESA/Hb = 100, this will mean that for an alpha level of 5% 
(95%CI) and a beta level of 5% (statistical power of 95%) we shall need 30 patients in 
each group. We assume that there will be a 50% drop out (transplantation and patient 
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9 Data Handling & Record Keeping 
9.1 Confidentiality  
The Chief Investigator has a responsibility to ensure that patient confidentiality is 
protected and maintained. They must also ensure that their identities are protected 
from any unauthorised parties. Information with regards to study patients will be kept 
confidential and managed in accordance with the Data Protection Act, NHS Caldicott 
Guardian, The Research Governance Framework for Health and Social Care and 
Research Ethics Committee Approval. 
 
The Investigator as well as the study team must adhere to these parameters to ensure 
that the Patient’s identity is protected at every stage of their participation within the 
study. To ensure this is done accordingly, each patient, at time of consent must be 
allocated an unique screening number by either the PI or a member of the study team 
before undergoing any screening procedures.The patients initials (the first letter of 
their first name and the first letter of their last name) should be used as a means of de-
identifying  parameters. This information should be kept on a screening log, which 
should be updated accordingly throughout the study. Once the patient has completed 
screening procedures and is enrolled onto the study, the patient will be allocated a 
randomisation number and entered on an enrolment log. 
 
 
If any patient information needs to be sent to a third party (including 
correspondence/communication to central laboratories, CROs, sponsor) the PI and the 
study team should adhere to patient de-identified parameters. This includes the patient 
initials, date of birth, gender as well as the unique study ID/randomisation number. 
Any information that is to be collected by these third parties will utilise these coded 
details for any revelant documents as well as maintaining databases. 
 
• What identifiable information will be collected from the subjects? Nil 
expected. 
• Who will have access to the Information and why? Only researchers or those 
required for audit of study 
• The Chief Investigator is the ‘Custodian’ of the data. 
• Patient identifiable details will not be transferred outside the EU. 
• The patients will be anonymised with regards to any future publications 
relating to this study. 
 
9.2 Case Report Form  
CRF Data Collection Summary 
 Screening Consent Run-in Treatment Off-
Treatment 
FU 
Informed Consent  x    
Inclusion/Exclusion 
Criteria check  
x x    
Medical History Recorded 
(in full) 
x     
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Vital Signs (Blood 
Pressure) 
x  x x x 
PET-CT   x  x 
Cardiac MR   x  x 
Weight x  x x  
ESA dose x  x x X 
Current Medical 
Conditions  
  x x x 
Adverse Event    x x x 
Concomitant Medications  x  x x x 
Local Lab assessment  x  x x x 
Demographics (including 
Date of Birth and Gender)  
x     
 
9.3 Record Retention and Archiving 
During the course of research, all records are the responsibility of the Chief 
Investigator and must be kept in secure conditions. When the research trial is 
complete, it is a requirement of the Research Governance Framework and Trust 
Policy that the records are kept for a further 20 years. For trials involving BH Trust 
patients, undertaken by Trust staff, or sponsored by BHT,, the approved repository for 
long-term storage of local records is the Trust Modern Records Centre which is based 
at 9 Prescot Street.  
 
9.4 Compliance 
The CI will ensure that the trial is conducted in compliance with the principles of the 
Declaration of Helsinki (1996), the principles of GCP and in accordance with all 
applicable regulatory requirements including but not limited to the Research 
Governance Framework and the Medicines for Human Use (Clinical Trial) 
Regulations 2004, and all subsequent amendments, Trust and Research Office policies 
and procedures and any subsequent amendments. 
 
9.5 Clinical Governance Issues 
9.5.1 Ethical Considerations 
This protocol and any subsequent amendments, along with any accompanying 
material provided to the patient in addition to any advertising material will be 
submitted by the Investigator to an Independent Research Ethics Committee. Written 
Approval from the Committee must be obtained and subsequently submitted to the 
JRMO to obtain Final R&D approval, prior to any activity taking place or changes 
implemented. 
 
9.6 Quality Control and Quality Assurance 
9.6.1 Summary Monitoring Plan 
Refer to PEAR  Monitoring Plan for further details 
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The first monitoring visit is due within three months of the first patient being enrolled 
at a site.  Thereafter monitoring visits will occur every four months. The monitoring 
will be a combination of completion of self monitoring forms and a yearly onsite visit. 
  
Source data verification (SDV) will be performed, as detailed in the monitoring plan. 
This will involve direct access to patient notes and include the review of consent 
forms and other relevant investigational reports.  Missing data will be sought, unless 
confirmed as not available. 
 
Non-commercial central laboratories will be monitored though on site and self 
monitoring during their participating in the trial, as detailed in the monitoring plan. 
 
9.6.2 Audit and Inspection 
This study may be audited by representatives from the sponsor or IMP supplier.  The 
investigator will be informed of any audit outcome.  Investigators are obliged to 
cooperate in any audit, allowing the auditor direct access to all relevant documents 
and allocate his/her time and the time of his/her staff to the auditor to discuss any 
findings or issues.  Audit may occur at any time during or after completion of the 
study. 
 
Inspections may be carried out by the Competent Authority at any time and the 
investigator should notify the sponsor immediately if there are any such plans for an 
inspection. 
 
9.7 Serious Breaches in GCP or the Trial Protocol 
The sponsor of the Clinical Trial is responsible for notifying the licensing authority in 
writing of any serious breach of: 
 
The conditions and principles of GCP in connection with that trial; or 
The protocol relating to the trial, as amended from time to time in accordance with 
regulations 22 to 25, within 7 days of becoming aware of that breach. 
 
For the purposes of this regulation, a ‘serious breach’, is a breach which is likely to 
effect to a significant degree: 
The safety or physical or mental integrity of the subjects of the trials; or 
The scientific value of the trial. 
 
The CI is responsible for reporting any serious breaches to the sponsor (JRMO) 
within 24 hours. The sponsor will notify and report to the MHRA within 7 working 
days of becoming aware of the serious breach.     
 
9.8 Non-Compliance        
Is defined as a noted systematic lack of both the CI and the study staff adhering to 
SOPs/protocol/ICH-GCP and UK regulations, which leads to prolonged collection of 
deviations, breaches or suspected fraud. 
 
These non-compliances may be captured from a variety of different sources including 
monitoring visits, CRFs, communications and updates. The sponsor will maintain a 
log of the non-compliances to ascertain if there are any trends developing which to be 
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escalated. The sponsor will assess the non-compliances and action a timeframe in 
which they need to be dealt with. Each action will be given a different timeframe 
dependant on the severity. If the actions are not dealt with accordingly, the JRMO will 
agree an appropriate action, including an on-site audit. 
 
10 Trial Committees 
The chair the Data Safety Committee will not be an active member of PEAR. The 
committee will review the progress of the study and issues arising from the study. 
This will include review of SAE to determine if there are any trends that would 
suggest concerns about the conduct of the study. 
  
A separate Renal Research committee meets regularly throughout the year. Concerns 
of CI or study members about this study can be discussed at this forum to provide 
external expertise. 
 
11 Publication Policy  
Only anonymised data will be used for publication. We shall attempt to publish results 
in peer reviewed journals. 
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Appendix 1: PET Imaging Protocol 
Abbreviations 
CECM Centre for Experimental Cancer Medicine 
CT Computed tomography 
FDG Fluorodeoxyglucose 
IMP Investigational Medicinal Product 
MDT Multi Disciplinary Team 
PET Positron Emission Tomography 
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This manual summarises the agreed PET protocol for assessing the whole body 
distribution of arterial inflammation in renal failure patients. The patients in this study 
will have confirmed renal failure and will be on dialysis. 
 
1.1. PET/CT 
All PET acquisitions should be accompanied by a low-dose CT procedure to allow for 
attenuation correction and co-localisation of PET data. The parameters of these CT 










As plasma clearance in these patients is delayed, dynamic imaging from 0 to 60 
minutes over the area starting from the Arch of the Aorta (upper limit: arch of the 
Aorta and lower limit: the axial extent of PET Field-of-View) will be performed 
followed by whole body imaging at 90minutes’ 
 
1.2.1. Glucose Measurement 
Patients undergoing FDG-PET/CT should have a blood glucose measurement carried 
out prior to administration of 18F-FDG. FDG administration should only proceed if 
blood glucose is < 10.0 mmol/l. 
 
1.2.2. Dose 
The administered activity of 18F-FDG should be < 200 MBq due to renal failure in 
these patients. 200MBq must not be exceeded. 
1.2.3. Type of scan 
Helical CT acquisition for the low-dose CT from the base of the skull to the knee 
joints. 
Whole Body PET data: Multiple bed positions should be acquired from the knee 
joints to the base of the skull. The time per bed position should be 2 minutes and the 
PET data acquisition should not exceed a total of 30 minutes. 
 
1.2.4. Uptake period 
Dynamic scan start at injection time (20 seconds delay); followed by whole body scan 
at 90 minutes from injection time. 
1.2.5. Total Scan time 
 
No more than 1 x 60 minutes and 1 x 35 minutes (max. 30 min PET emission).  
Blood sampling: 3 samples (3mls each ) at minutes 1, 2 and 3 form the injection of 
activity; then 3 samples (3mls each) at minutes 5, 7 and 9 followed by 5 samples at 
19, 29, 39, 49 and 59 minutes) ( total 11 samples =33 mls blood smaple per scan) 
 
 
1.2.6. FDG-PET Local Analysis 
 
Image analysis will be performed on a dedicated workstation. Using the CT images, 
the vasculature will be divided into carotid arteries, the aorta, iliac and femoral 
arteries. The common and external iliac arteries will be combined and treated together 
as ‘‘iliac artery’’; similarly, the common femoral and superficial femoral arteries are 
amalgamated into the single label of ‘‘femoral artery.’’ The transition point between 
iliac and femoral arteries is the inguinal ligament. 
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Arterial 18F-FDG uptake (as a measure of arterial inflammation) in the legs and neck 
are measured by drawing a region of interest (ROI) around the artery on every slice of 
the coregistered transaxial PET/CT images. On each image slice, the mean and 
maximum standardized uptake values (SUVs) of 18F-FDG in the ROI (containing the 
arterial wall and the lumen) are calculated as the mean and maximum pixel activity. 
The SUV is the decay-corrected tissue concentration of 18F-FDG (in kBq/g), adjusted 
for injected 18F-FDG dose and body weight (in kBq/g), and is a well-recognized 
method for quantification of 18F-FDG PET data. 
By averaging SUVs for all artery slices within an arterial territory, mean and 
maximum SUVs can be derived for each region. These SUVs are normalized to blood 
18F-FDG activity by division by an average blood ROI (at least 8 venous ROI 
measurements), estimated from either the inferior vena cava (leg studies) or the 
jugular vein (carotid studies). This calculation results in an arterial TBR measure, 
which is reported subsequently. 
PEAR 




12 APPENDIX 2: Image Acquisition Form 
ACQUISITION DATA  
 
Type of Scan: 
 
FDG-PET/CT        
 
Scan acquired at: 
(Name of department / PET Centre) 
 
Patient initials:  
Patient date of birth:  
Patient trial number:  
Referring Consultant / Study 
Name or Code:  
Consultant telephone number:  




Date of scan:  
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Full Title                                   PEAR study: experimental outcomes version 
 
 
Sponsor   
                                                          Queen Mary, University of London  
 
Contact person of the above sponsor 
organisations is: 
  
 Head of Research Resources 
Joint Research Management Office 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7260 
 Email: sponsorsrep@bartshealth.nhs.uk 
 
 
REC Reference  
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18.  
2. GLOSSARY  of Terms and Abbreviations 
 
 
AE   Adverse Event   
AR   Adverse Reaction 
ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
GAfREC Governance Arrangements for NHS Research Ethics 
Committees 
ICF   Informed Consent Form 
JRMO   Joint Research Management Office 
NHS REC  National Health Service Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
Participant  An individual who takes part in a clinical trial 
PI   Principal Investigator 
PIS   Participant Information Sheet  
QA   Quality Assurance 
QC   Quality Control 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
TMG   Trial Management Group 
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3. SIGNATURE PAGE 
 
 
Chief Investigator Agreement 
 
 
The clinical study as detailed within this research protocol (Version 1.0, dated 
14.Nov.2014), or any subsequent amendments will be conducted in accordance with 
the Research Governance Framework for Health & Social Care (2005), the World 
Medical Association Declaration of Helsinki (1996) and the current applicable 
regulatory requirements and any subsequent amendments of the appropriate 
regulations. 
 
Chief Investigator Name: Prof. M.M. Yaqoob 
Chief Investigator Site:  Royal London Hospital 







Principal Investigator Agreement (if different from Chief investigator) 
 
 
The clinical study as detailed within this research protocol (Version 1.0, dated 
14.Nov.2014), or any subsequent amendments will be conducted in accordance with 
the Research Governance Framework for Health & Social Care (2005), the World 
Medical Association Declaration of Helsinki (1996) and the current applicable 
regulatory requirements and any subsequent amendments of the appropriate 
regulations. 
 
Principal Investigator Name: Dr. S. Fan 
Principal Investigator Site: Royal London Hospital 
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4.    SUMMARY/SYNOPSIS 
 
 
Short Title PEAR study : experimental outcomes  
Methodology 
 
Laboratory analysis of blood samples stored for future research 




Barts Health NHS Trust- Royal London Hospital 
Objectives/Aims 
 
To study the effect of Pentoxifylline on cytokine levels, 
leucocyte DNA telomere length shortening and Highly sensitive 











Analysis (if applicable) 
 
Analysis will include descriptive statistics, t-test, Paired-t 




Proposed Start Date 15.Dec.2014 
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5. INTRODUCTION  
 
Anaemia is a common complication of End Stage Renal Disease (ESRD). This usually 
happens as a result of reduced production of erythropoietin hormone by the kidneys. Anaemia 
as a result of ESRD is treated by giving injections of erythropoiesis stimulating agents (ESAs) 
which have an action similar to natural erythropoietin. 
 
Some patients with ESRD are less responsive or resistant to the action of ESAs consequently 
requiring higher doses of ESAs. High ESA requirement is a surrogate marker of increased all 
cause cardiovascular mortality & morbidity in ESRD patients. Elevated levels of inflammatory 
cytokines as chronic inflammation is one of the major factors associated with ESA hypo-
responsiveness. DNA telomere length shortening is another surrogate marker for 
cardiovascular risks in haemodialysis patients which is associated with chronic inflammation. 
 
There is emerging evidence for Pentoxifylline, a non-selective phosphodiesterase inhibitor as 
a potential treatment for ESA hypo responsiveness. Pentoxifylline (used for twenty years in 
the treatment of peripheral and cerebral vascular diseases), has potent haemorheological and 
anti-inflammatory properties (secondary to inhibition of phosphodiesterases). Pentoxifylline is 
associated with reduction of pro inflammatory cytokines such as tumour necrosis factor 
(TNF)-α, Interferon (IFN)- γ and Interleukin (IL)- 6 in haemodialysis and CKD patients as well 
as improving haemoglobin. 
 
Currently a Single Centre randomized placebo controlled, double blinded study to see if 
Pentoxifylline can help End Stage Renal Disease Patients with Erythropoietin Resistance 
(PEAR study) is underway at Barts Health NHS Trust (Rec number: 12/LO/1635  
 EudraCT Number: 2011/006168/30).  
 
 As a part of this research, some patients recruited in the study have consented for additional 
blood tests to be taken during the course of the study for future research.  Therefore we 
intend to investigate effect of pentoxifylline on cytokine levels, inflammation and consequently 
on DNA telomere length shortening in our patient group. 
 
 
6. TRIAL OBJECTIVES 
 
Primary Endpoint  
 
To study the effect of pentoxifylline on cytokine levels in ESRD patients on haemodialysis with 
hypo-responsiveness to erythropoiesis stimulating agents or ESAs. 
 
Secondary Endpoint  
 
To study effect of pentoxifylline on leucocyte DNA telomere length shortening and highly 
sensitive CRP levels 
 
7. METHODOLOGY  
  
Inclusion Criteria  
 
Not applicable for the proposed study as we are aiming to analyse stored samples 
collected from consenting patients during PEAR study. 
 
Exclusion Criteria  
 
        Not applicable for the proposed study as we are aiming to analyse stored samples  
         collected from consenting patients during PEAR study. 
 
Study Design / Plan  
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Pseudo-anonymised samples for future research are stored in Human Tissue Authority (HTA) 
approved lab will be analysed for cytokine levels, highly sensitive c reactive protein and 
leukocyte DNA telomere length shortening. Pseudo-anonymised samples will be unblinded at 
the end of relevant laboratory investigations.  Unblinding of lab samples will be done after 
unblinding for PEAR study done. However samples shall remain pseudo-anonymised. 
Samples will be analysed in batches.  
 
 
8. STUDY PROCEDURES   
 
Blood samples are only taken from the participants of PEAR study who have consented for 
samples to be stored for future research. Samples are pseudo-anonymised before storage. 
Samples will be analysed in batches. Results and relevant pseudo-anonymised data will be 
stored in secured trust computers. Available results will be correlated with intervention in 
PEAR study once PEAR study data is unblinded.  
 
9. STATISTICAL CONSIDERATIONS  
 
This is a pilot study generating hypothesis. Sample size considerations do not apply as this 
project involves analysing samples stored for future research as a part of PEAR Study. 
Analysis will include descriptive statistics, t test, Paired t variance and covariance and use of 
non-parametric statistics when required. 
 
 
10. ETHICS  
 
This study does not raise any significant ethical issues. This study falls into criteria of studies 
which do not require any formal ethics review as per the National Research Ethics (NRES) 
guidelines.  
 
Patients have already consented for blood tests to be done and stored for future research. 
Anonymity shall be maintained (pseudo-anonymised). Samples shall be stored in HTA 
approved laboratory. 
 
11. SAFETY CONSIDERATIONS: 
There are no safety concerns.  
 
12. DATA HANDLING AND RECORD KEEPING:  
- Confidentiality 
 
Information related to participants should be kept confidential and managed in 
accordance with the Data Protection Act, NHS Caldecott Principles, The 
Research Governance Framework for Health and Social Care, and the 
conditions of Research Ethics Committee Approval. 
 
- Record Retention and Archiving 
 
When the research trial is complete, the data will be stored as per research 
Governance Framework and Trust Policy that the records are kept for a 
further 20 years.  
 
 
13. LABORATORIES : 
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Samples will be processed in Immunology/Serology Laboratory at Royal London Hospital. No 
additional laboratory preparation is required.  
 
Samples have already been pseudo-anonymised at the time of collection. A detailed log of 
samples taken to laboratory for analysis will be maintained. Optimal temperature conditions 
will be maintained during the transit to maintain viability of the samples.  
  
 




Cytokine assays will be done using commercially supplied kits (R&D Systems) using standard 
manufacturer’s protocol for analysis. Initially the specific anti-cytokine antibody (capture 
antibody) is bound to a polystyrene microplate. Unbound capture antibody is then washed 
away. Plates are blocked and washed. Samples or standards are added and any chosen 
cytokine present is bound by the immobilized antibody. Unbound materials are then washed 
away. Streptavidin-Horseradish Peroxidase (HRP) is used to bind to the detection antibody. 
Unbound streptavidin-HRP is washed away. Tetramethylbenzidine (TMB) substrate solution 
is added to the wells and a blue colour develops in proportion to the amount of analyte 
present in the sample. Colour development is stopped turning the colour in the wells to 
yellow. The absorbance of the colour at 450 nm is measured. 
 
DNA telomere length analysis:  
 
 
Telomere length will be measured by a qPCR assay that compares the mean telomere repeat 
sequence copy number (T) to a reference single-copy gene copy number (S) in each sample 
which is then validated by comparison with Southern blot terminal restriction fragment 
analysis. PCRs to be conducted using a Qiagen Rotor-Gene Q real time PCR cycler (Qiagen, 
Manchester UK). Telomere length was measured in T/S ratio units. The relative quantity of 
the single copy gene (S) in each experimental sample was expressed as the level of dilution 
of the reference DNA sample needed to match it to the experimental sample with regard to 
the number of cycles of PCR needed to generate a given amount of single copy gene PCR 
product during the exponential phase of the PCR (T). For each experimental sample the ratio 
of these dilution factors is the relative telomere to single copy gene (T/S) ratio. Thus T/S = 1 
when the unknown DNA is identical to the reference DNA in its ratio of telomere repeat. 
 
15. SAFETY REPORTING  
 





16. MONITORING &AUDITING 
 
Will be done as per according to the protocol, sponsor's standard operating procedures 




17. TRIAL COMMITTEES 
 
This usually consists of the CI, PI and investigator Dr. Tarun Kaushik.  Trial 
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18. FINANCE AND FUNDING 
Barts Cardiovascular Biomedical Research Unit (BRU) is funding the project.  
 
 
19. INDEMNITY  
 
Indemnity will be provided by the sponsor, 
Joint Research Management Office RMO,  
Queen Mary University of London, 
Queen Mary Innovation Centre, 
5, Walden Centre 
London E1 2EF.  
 
 
20. DISSEMINATION OF RESEARCH FINDINGS: 
 
Study results disseminated in internal report, conference presentations and peer 






Dr. Tarun Kaushik 
Clinical Research Fellow 
Wlliam Harvey Research Institute 
Queen Mary University, London 
Charter House square, 
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Patient Information for Study: 
PEntoxifylline in Anaemia Resistant to erythropoietin (PEAR) 
 
Chief  Investigator:  Prof M Yaqoob, Barts Health NHS Trust  
Principal Investigator:   Dr Fan 
    
 
 ‘You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully. Talk to others about the study if you wish.  
• Part 1 tells you the purpose of this study and what will happen to you if you take part.   
• Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
 
Part 1. 
What is the purpose of the study? 
 
Pentoxifylline 
Pentoxifylline has been widely used for over 20 years to treat people with circulation 
problems (both of the legs and the brain). The drug is generally very safe.  
 
In addition to its effect on circulation, people have noticed that it also has potent anti-
inflammatory properties.  
 
Inflammation is often the reason why people on dialysis are anaemic (have low Hb) despite 
the use of a hormone called erythropoietin stimulating agent (ESA or otherwise commonly 
called EPO). A small study showed that this treatment could improve the Hb level of patients 
who did not originally respond to EPO. Unfortunately the study was small and needs to be 
repeated before we can be sure it is effective. 
 
Research Study Question 
We want to treat 2 groups of patients. One will receive Pentoxifylline and  the other will 




Why have I been chosen? 
We have invited you to help us because you have been identified as requiring a high dose of 
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Do I have to take part? 
‘No.  It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to withdraw 
at any time and without giving a reason.  A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive’.  
 
What will happen to me if I take part? 
If you agree to take part, we will ask you to sign a consent form. 
 
Sometimes we don’t know which way of treating patients is best. To find out, we need to 
make comparisons between the different treatments. We put people into groups and give each 
group a different treatment; the results are compared to see if one is better. To try to make 
sure the groups are the same to start with, each patient is put into a group by chance 
(randomly). The results are then compared. 
 
We will randomly put you into either the Pentoxifylline or Placebo group. You will have a 
50:50 chance of being put into the Pentoxifylline treatment group, but neither you nor your 
doctor will know (the study is “blinded”).  
 
If you are in the study, you will be treated for 6 months. During these 6 months, you will be 
reviewed regularly by a member of the Research Team. We shall also take 2 extra blood tests 
every month (2 teaspoonfuls) from your dialysis machine. These blood tests are designed to 
look at how you respond to your EPO and how much “inflammation” is in your body. It also 
involves studying your DNA. At the end of the 6 months, you will stop the tablets, but we 
will still monitor your blood tests every 2 weeks for 2 months.  
 
You will also have special “X-Rays” that are designed to look at your heart and blood 
vessels. These tests will be done over a 2-hour period and you will be asked to attend the 
hospital. You will have an X-ray test before and at the end of the study. One of the X-ray test 
is called a “PET-CT”. This involves an injection of a radioactive dye. Blood will then be 
taken at regular intervals over 1 hour (about 60mLs). The level of radioactivity is 6 times the 
normal background radiation level in the UK. It will not affect your routine daily life. You 
will also have another special X-Ray called “Magnetic Resonance” (MRI) scan that looks at 
your heart. If you are afraid of being in closed spaces (claustrophobic) or if you have any 
metallic implants such as a hip replacement or a pacemaker, you must tell us as you will not 
be able to have this scan. 
 
Your general renal / dialysis care will not be affected. Your participation in this study will not 
affect the chances of you getting a kidney transplant.  
 
Expenses and payments: 
Most visits will be carried out when you come in for dialysis. There will be two extra visits 
for the specialized X-ray tests.  We shall arrange the transport for you or reimburse any extra 
travel costs that you incur. 
 
What do I have to do? 
If you agree to do this study, you will need to take the tablets we select for you once a day  
for 6 months. You will have a few extra blood tests (taken when you are on dialysis) and 
special X-rays that will require 2 extra visits to the hospital. If you have a problem or if you 
dislike your treatment, you can withdraw from the study at any time. Other aspects of your 
care will not be affected. 
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What is the treatment that is being tested? 
Pentoxifylline is made by a company called Sanofi. It is mainly used to treat people who have 
circulatory problems. But there is some evidence that it will also help your haemoglobin 
level.  
 
What are the alternatives for treatment? 
EPO is used to correct low haemoglobin levels in patients with renal failure. Unfortunately, 
not everyone responds to this hormone or needs a very high dose that can cause side effects 
and problems. You have been identified as someone who requires high doses of EPO. People 
like you may benefit if we find a treatment that makes you respond to EPO better. 
 
 
What are the side effects of any treatment received when taking part? 
Pentoxifylline is widely used for patients with circulation problems. The drug can increase 
bleeding. The use of Asprin and other anti-coagulants is safe with Pentoxifylline. If you are 
concerned about bleeding or have an increased tendency to bleed, please let us know. 
 
Other side-effects are relatively rare but can include gastro-intestinal disturbance and 
headaches.  
 
Some people can be allergic to Pentoxifylline or the “Dummy drug” which is composed of 
cellulose. If you are known to be allergic to either please let us know as you are not suitable 
for the study. 
 
If you develop any side-effects or are concerned about the tablets/treatment, please contact us 
at any time. Details are provided below. 
 
What are the other possible disadvantages and risks of taking part? 
We think the risk of taking part is very low.  
 
It is possible that Pentoxifylline is not effective at improving your Hb, but we will not be 
stopping or reducing you EPO. 
 
If you have private medical insurance you should check with the company, before agreeing to 
take part in this study. 
 
Harm to the unborn child   
There is no evidence that Pentoxifylline is harmful to any unborn child. Nevertheless, we 
would advise that you take adequate precaution against getting pregnant during the study. 
 
If you think you may be pregnant, you should tell us. 
If you are trying to get pregnant, you should not take part in this study. 
 
If you are of child bearing age, we will ask if you have missed your periods or if you think 
you might be pregnant before we do any “X-rays”. If there is any doubt, we will do a 
pregnancy test before exposing you to “X-rays”. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get might help improve 
the treatment of people on dialysis. 
 
PEAR study 
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You have been identified as someone who does not respond well to EPO. This makes you at 
risk of becoming anaemic and getting side effects from EPO. If you are randomized to 
Pentoxifylline, you may respond better to EPO. If you are randomized to the “dummy” tablet, 
you will not get any potential benefit from Pentoxifylline. However, the study team will keep 
a close eye on your results throughout the study and make sure your treatment is adjusted 
according to the dialysis unit’s guidelines. This “study effect” has been seen in many 
different studies and can be quite significant. 
 
 
What happens when the research study stops? 
At the end of the study, you will stop your treatment. However, Pentoxifylline is a licenced 
drug and can be continued if you need it. 
 
 
What if there is a problem? Who can I contact? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2.    
 
If you have any complaints or have any questions, please contact: 
 
 Research Nurse:        Mr. Wancheung Li (through Royal London Hospital switch board) 
Consultant in charge:        Tel:020 3594 2674 (Dr Fan) or 020 3594 2658 (Prof Yaqoob) 
 
In emergencies, please contact the Renal Registrar on call: Tel: 020 7377 7000 
 
Alternatively, you can contact: 
Patient Advice and Liaison Service (PALS) 
Telephone: 020 7943 1335, Minicom: 020 7943 1350 
E-mail: pals@bartsandthelondon.nhs.uk 
 
Will my taking part in the study be kept confidential?  
All information which is collected about you during the course of the research will be kept 
strictly confidential.  If you consent to take part in the research the people conducting the 
study will abide by the Data Protection Act 1988, and the rights you have under this Act.   
  All the information about your participation in this study will be kept confidential.  The 
details are included in Part 2.’ 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any decision. 
 
 
Part 2  
 
What if relevant new information becomes available?   
 Sometimes during the course of a research project, new information becomes available about 
the treatment/drug that is being studied.  If this happens, your research doctor will tell you 
about it and discuss whether you want to or should continue in the study.  If you decide not to 
carry on, your research doctor will make arrangements for your care to continue.  If you 
decide to continue in the study you will be asked to sign an updated consent form. 
 
PEAR study 
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Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He/she will explain the reasons and arrange for 
your care to continue. 
 
If the study is stopped for any other reason, you will be told why and your continuing care 
will be arranged. 
 
 
What will happen if I don’t want to carry on with the study? 
If you chose to withdraw from the study any information that has been already collected will 
be processed as part of the study. 
 
If you stop the treatment, we will ask if you are willing to have a 1-month “Off-Treatment” 
follow-up. This is important as we want to see what happens to your blood results and Hb 
levels after you come off the treatment. We shall also ask if you are willing to have the end of 
study “X-rays”.  
 
You are free to say “no” to the “off-treatment follow-up”, the extra blood tests or to the “X-
rays”. However, you should be aware that audits are conducted on a regular basis as required 
by Good Clinical Governance. Results of blood tests that are taken as part of your regular 
medical care will continue to contribute towards our audit and reporting to Department of 
Health mandated registries. 
 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (See contact details that are listed 
in Part 1 of this form).  If you remain unhappy and wish to complain formally, you can do 
this through the NHS Complaints Procedure.  Details can be obtained from the hospital. 
 
Harm:   
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements.  If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation against 
Barts Health NHS Trust, but you may have to pay your legal costs.  The normal National 
Health Service complaints mechanisms will still be available to you (if appropriate).’ 
 
NHS Indemnity does not offer no-fault compensation i.e. for non-negligent harm, and NHS 
bodies are unable to agree in advance to pay compensation for non-negligent harm.  They are 
able to consider an ex-gratia payment in the case of a claim. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  If you consent to take part in the research the people conducting the 
study will abide by the Data Protection Act 1988, and the rights you have under this Act.   
 
Information including details of your treatment and details about any infection you may 
develop during the study will be collected and entered into a database. This will be coded and 
the investigators will keep the code. People that are not involved in the study will not have 
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Involvement of the General Practitioner/Family doctor (GP)  
Unless you object, we will inform your GP that you are taking part in this study and details 
about your treatment. We think this is important so they know what tablets you are taking.  
 
What will happen to the results of the research study? 
We hope the results of our study will be important to all doctors looking after patients 
undergoing HD. We will therefore publish the results and present the data at various 
meetings. However, at all times, your confidentiality will be protected. You will NOT be 
identified in any report/publication unless we ask you for specific permission. 
 
 
Who is organising and funding the research?   
Barts Health NHS Trust is organising and running this study.  
 
Who has reviewed the study?  
This study was given a favourable ethical opinion  for conduct in the NHS by the East 
London and The City Research Ethics Committee. The detailed study has also been carefully 
considered by an independent internal research committee of the Renal Unit at BHT 
 
You may wish to thank your participant for considering taking part or taking time to 
read this sheet. 
 
 
T H E  R O Y A L  H O S P I T A L  O F  S T  B A R T H O L O M E W ,  T H E  R O Y A L  L O N D O N  H O S P I T A L  A N D  T H E  L O N D O N  C H E S T  H O S P I T A L  N H S  
T R U S T  
 
Centre Number: :                    Patient Id:: 
CONSENT FORM 
 
Title of Project: PEntoxifylline in Anaemia Resistant to 
erythropoietin (PEAR) 
 
Name of Researcher: Prof M Yaqoob      Please initial box 
1. I confirm that I have read and understand the information sheet dated 29th Oct. 2013 for the above  
study. I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily.           
                                                                                                                                               c 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected.            c 
 
3. I understand that relevant sections of any of my medical notes and data collected during the study, 
may be looked at by responsible individuals from Barts and The London or from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records.     c 
 
4. I agree to my GP being informed of my participation in the study.    c 
 
5. I agree to take part in the above study.        c 
 
6. I understand that blood will be taken during my treatment / investigation and will not be used for 




________________________ ___________________ ______ 
Name of Patient Signature Date 
 
 
_________________________ ________________ ________ 
Name of Person taking consent Signature  Date 
 (if different from researcher) 
 
 
_________________________ ________________ ________ 
Researcher  Signature Date 
 
 




NRES Committee London - City & East 
Bristol Research Ethics Committee Centre 
Whitefriars 








05 March 2013 
 
Professor Magdi Yaqoob 
Barts and The London 




Dear Professor Yaqoob, 
 
Study title: A Single-Centre randomized placebo controlled, double 
blinded study of Pentoxifylline in End-Stage Renal 
Disease Patients with Erythropoeitin resistance 
REC reference: 12/LO/1635 
EudraCT number: 2011-006168-30 
Amendment number: AM01 Substantial Amendment 01 dated 04 Dec 2012 
Amendment date: 22 February 2013 
IRAS project ID: 103187 
 




The members of the Committee taking part in the review gave a favourable ethical opinion 





The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Participant Consent Form: Participant Consent Form  4  28 August 2012  
Participant Information Sheet: Participant Information Sheet  4  28 August 2012  
European Commission Notification of Substantial Amendment Form  AM01 
Substantial 
Amendment 
01 dated 04 
Dec 2012  
22 February 2013  
Covering Letter    27 September 2012  
Protocol  7-1  27 November 2012  
  
 
Membership of the Committee 
 





All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out 
the ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees 
and the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 










Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to:  Mr Gerry  Leonard, Barts Health NHS Trust 
 
NRES Committee London - City & East 
 
Attendance at Sub-Committee of the REC meeting on 25 February 2013 
 
Name   Profession   Capacity    
Professor Atholl Johnston  Professor of Clinical Pharmacology  Expert  
Dr Arthur T. Tucker  Principal Clinical Scientist & Honorary 
Reader, (REC Chairman)  
Expert  
Professor David Wingate  Gastroenterologist  Expert  
  
Also in attendance:  
 
Name   Position (or reason for attending)   
Mr  Rajat Khullar  Committee Coordinator  
 
 

